ab 20 July 2026 Global Research Fast Take Shenzhen New Industries Biomedical Headline 2026 ESOP draft announced, aiming for 15% revenue CAGR in 2025-27 (VA consensus: 12.5% / UBSe: 8.9%) Our Take Positive. Details include: 1) Potential incentives: 0.5273% of share capital; 2) Grant price: Rmb35/share (25% below last close); 3) Vesting criteria: 15% sales CAGR in 2025-27. However, IVD test fee unification remains the biggest downside risk. Equities | China | | | --- | --- | | Medical Supplies | | | 12-month ...